OncoMatch/Clinical Trials/NCT06889610
A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
Is NCT06889610 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including MTT(Multimodal Tumor Thermal Therapy System)- Colorectal Cancer and MTT(Multimodal Tumor Thermal Therapy System)- Triple-Negative Breast Cancer for triple negative breast cancer metastatic.
Treatment: MTT(Multimodal Tumor Thermal Therapy System)- Colorectal Cancer · MTT(Multimodal Tumor Thermal Therapy System)- Triple-Negative Breast Cancer · MTT(Multimodal Tumor Thermal Therapy System)- Melanoma — This study focuses on the treatment of liver metastases from three common cancers: colorectal cancer, triple-negative breast cancer and melanoma. Currently, there are limitations in the treatment of liver metastases of these cancers. Multimodal thermophysical ablation therapy can reshape the tumor microenvironment, release neoantigens, and act as an in-situ vaccine. On this basis, the combination of multimodal ablation with immunotherapeutic drugs such as pucotenlimab will be explored. The efficacy and safety of this combination therapy in patients with liver metastases of solid tumors will be investigated, with the expectation of breaking through the existing treatment limitations.
Check if I qualifyExtracted eligibility criteria
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Melanoma
Colorectal Cancer
Biomarker criteria
Required: ESR1 expression <1% (<1% nuclear staining)
triple-negative defined as <1% nuclear staining for ER and PR expression and HER2 negative
Required: PR (PGR) expression <1% (<1% nuclear staining)
triple-negative defined as <1% nuclear staining for ER and PR expression and HER2 negative
Required: HER2 (ERBB2) negative (negative)
triple-negative defined as <1% nuclear staining for ER and PR expression and HER2 negative
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic drug therapy — second-line
Patients who have failed standard second-line drug therapy
Must have received: systemic drug therapy — first-line
Patients who have failed standard first-line drug therapy
Must have received: PD-1 monoclonal antibody
including those who have failed PD-1 monoclonal antibody therapy, with progression within six months of adjuvant or neoadjuvant therapy considered as first-line therapy failure
Cannot have received: Pucotenlimab (Pucotenlimab)
Patients who have previously received Pucotenlimab treatment
Lab requirements
Blood counts
wbc ≥3.0×10^9/l; anc ≥1.5×10^9/l; plt ≥75×10^9/l; hgb ≥90 g/l
Kidney function
cr ≤1.5×uln or crcl ≥60 ml/min
Liver function
child-pugh score ≤7, ast ≤5.0×uln; alt ≤5.0×uln; tbil ≤1.5×uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify